Boston Scientific Corporation

    [td_text_with_title custom_title=”Boston Scientific Corporation”]We are a leading innovator of medical solutions that improve the health of patients around the world.

    Our products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women’s health, and chronic pain conditions.

    We continue to innovate in these areas and are extending our innovations into new geographies and high-growth adjacency markets.[/td_text_with_title]

    [td_text_with_title custom_title=”Latest post”]

    Boston Scientific Initiates Study Evaluating New Fully Resorbable Scaffold Technology

    First Patients Enrolled in the FAST Feasibility Study MARLBOROUGH, Mass., July 20, 2015 /PRNewswire/ — Boston Scientific (NYSE: BSX) has initiated a study of the company’s first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation […]

    0 comments

    Boston Scientific Bronchial Thermoplasty Treatment Recognized By American College Of Allergy, Asthma And Immunology

    MARLBOROUGH, Mass., July 9, 2015 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announces that Bronchial Thermoplasty (BT) delivered by the Alair™ System has received support from the American College of Allergy, Asthma and  Immunology (ACAAI). BT is an outpatient procedure proven to reduce asthma attacks in adult patients with severe asthma.1 This demonstrates a growing clinical acceptance among […]

    0 comments

    Boston Scientific Initiates Global Study To Assess EMBLEM™

    Boston Scientific Initiates Global Study To Assess EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) In Primary Prevention Patients With Low Ejection Fraction MARLBOROUGH, Mass., June 22, 2015 /PRNewswire/ — Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for […]

    0 comments

    Boston Scientific Acquires American Medical Systems’ Urology Portfolio For Up To $1.65 Billion

    Boston Scientific Announces Definitive Agreement To Acquire American Medical Systems’ Urology Portfolio For Up To $1.65 Billion Combined Business to Advance Patient Care with Leading Solutions Across Major Urology Categories MARLBOROUGH, Mass., March 2, 2015 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Endo International […]

    0 comments
    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

    Boston Scientific is primarily known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries.[3] With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD).[4][5]

    History

    Boston Scientific was formed June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine.[6]

    Post-IPO

    The company went public through an IPO on May 19, 1992.[6]

    The Taxus Stent was approved in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.[3]

    In April 2004 the company announced that it had exercised an exclusive option to acquire Precision Vascular Systems, Inc., as part of a series of agreements between Boston Scientific and Precision Vascular in 2002 - for an undisclosed sum.[7] In June Boston acquired Advanced Bionics Corporation for $740 million in cash, plus earn out payments.[8] In December Boston completed its acquisition of Advanced Stent Technologies, Inc. for $120 million payable in Boston Scientific stock, plus the possibility of future contingent payments. AST had been developing stent and stent delivery systems specifically designed to address the anatomical needs of coronary artery disease in bifurcated vessels.[9]

    In April 2005, Boston exercised an exclusive option to acquire TriVascular, Inc. for an undisclosed sum. TriVascular was founded in 1998 to develop less-invasive medical devices and procedures for treating abdominal aortic aneurysms.[10] In the same month the company also announced it had exercised its option to acquire CryoVascular Systems, Inc. and its proprietary angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries.[11] In June Boston Scientific announced that its wholly owned subsidiary, Nemo I Acquisition, Inc., had successfully acquired Rubicon Medical Corporation, with Rubicon became a wholly owned subsidiary of Boston Scientific.[12]

    Guidant merger

    In January 2006, the company announced an offer for Guidant of $72 per share or $25 billion[13], this offer was however, rejected. On April 21, the company acquired longtime competitor Guidant for $27.2 billion. Guidant was split between Boston Scientific and Abbott Laboratories.[14][15]

    Post-merger

    In December 2007, Boston Scientific announced it would sell its Fluid Management and Venous Access businesses for $425 million to Avista Capital Partners.[16]

    In April 2008 the company acquired CryoCor, Inc. for $1.35 per share, $17.6 million in total.[17][18]Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.[19]

    In January 2009, Boston announced it would acquire Labcoat Limited, whose primary development was that of a development-stage drug-eluting stent - for an undisclosed sum.[20]

    In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others.[21] In the same month Boston Scientific acquired Asthmatx, Inc. for $193.5 million, with payments of up to $250 million being paid on the achievement of specified revenue-based criteria through 2019.[22]

    In January 2011 Boston acquired Atritech, Inc. for $100 million plus additional potential payments of up to $275 million. Atritech developed a novel device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke.[23] In the same month Boston Scientific acquired Intelect Medical, Inc. for $78 million[24] and the remaining 86 percent of Sadra Medical, Inc. not already owned for $193 million plus contingent payments.[25] At the same time, the business divested its neurovascular business to Stryker Corporation for $1.5 billion.[26]

    In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 billion, paid out incrementally as various revenue milestones were achieved.[4] In September the company announed it would acquire BridgePoint Medical, Inc., developer of a catheter-based system to treat coronary chronic total occlusions.[27] In October, the company acquired Rhythmia Medical, Inc., developer of mapping and navigation methods for use in cardiac catheter ablations and other electrophysiology procedures.[28] A month later the business acquired catheter-based renal denervation system developer, Vessix Vascular, Inc..[29]

    In November 2013 Boston announced it would acquite Bard EP, the electrophysiology business of C.R. Bard, Inc.[30] for $275 million.[31]

    In May 2014 Boston acquired hysteroscopic intrauterine tissue removal specialist, IoGyn, Inc..[32] In September, the business announced it would acquire the Interventional business of Bayer.[33]

    In March 2015, the company announced it would acquire Endo International Plc's American Medical Systems urology business for at least $1.6 billion, expanding the company's health and prostate treatments.[34] In April, Boston announced its intention to acquire Xlumena, Inc..[35] In October Boston announced it had invested further in percutaneous mitral valve replacement system developer, MValve Technologies, gaining a right to acquire the business in the future.[36]

    In July 2016 the business acquired the manufacturer of radiofrequency ablation systems, Cosman Medical, Inc..[37] In September, Boston announced it had acquired EndoChoice Holdings, Inc., becoming part of the Boston Scientific Endoscopy business for $8.00 per share or $210 million in total.[38] In November the company acquired the gynecology and urology portfolio of Distal Access, LLC, a company that designs minimally invasive medical devices.[39] In December 2016, the business acquired a 15% stake in Neovasc, Inc. for $75 million.[40]

    In May 2017 the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices.[41] In October Boston acquired Apama Medical Inc. for up to $300 million.[42]

    In April 2018 Boston Scientific announced the triple closure of its acquisitions of women's health company, nVision Medical Corporation[43], NxThera[44] and Securus Medical Group, Inc. for up to $50 million.[45]

    Lawsuits

    Johnson & Johnson lawsuits

    Beginning in 2003, Boston Scientific and Johnson & Johnson were involved in a series of litigations involving patents covering heart stent medical devices. Both parties claimed that the other had infringed upon their patents. The litigation was settled once Boston Scientific agreed to pay $716 million to Johnson & Johnson in September 2009 and an additional $1.73 billion in February 2010.[46]

    It was announced in November 2014 that Johnson & Johnson would have another chance for payback after a multibillion-dollar trial was set for 20 November 2014. A New York federal court judge would hear the case without a jury to decide whether Boston Scientific should be held liable for the contract breach.[47]

    Transvaginal mesh

    Boston Scientific is one of several manufacturers of a medical device called transvaginal mesh, a type of surgical mesh used to treat pelvic organ prolapse. In 2015, Boston Scientific announced it would pay $119 million to 2,970 lawsuit plaintiffs, who had been injured by the mesh.[48]

    On Sunday, May 13, 2018, 60 Minutes broadcast a story suggesting that Boston Scientific used counterfeit Marlex polypropylene resin to manufacture their mesh product.[49] Boston Scientific responded by saying the broadcast was "irresponsible and misleading,"[50] citing a 2017 Food and Drug Administration (FDA) report stating that although they found variability in the polypropylene resin, "these differences do not present new safety or effectiveness concerns."[51]

    The Mayo Clinic has described the advantages and risks associated with the use of transvaginal mesh.[52]

    Restatement

    On Nov 3,1998, Boston Scientific restated its financial results for 1997, as well as its quarterly results for the first three quarters of 1998, due to the occurrence of business irregularities in the operations of its Japanese subsidiary.[53]

    Notes

    1. ^ "CEO Mahoney to be chairman of Boston Scientific". 
    2. ^ a b http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/annual-report-and-financial-statement-2017.pdf
    3. ^ a b Shelley Wood (4 Mar 2004). "FDA approves Taxus paclitaxel-eluting stent". www.medscape.com/. Retrieved 20 Feb 2015. 
    4. ^ a b "Boston Scientific Closes Cameron Health Acquisition". PR Newswire. UBM PLC. 8 June 2012. Retrieved 26 February 2016. 
    5. ^ "EMBLEM S-ICD System". Boston Scientific. Archived from the original on 26 February 2016. Retrieved 26 February 2016. 
    6. ^ a b "About Us - History". www.bostonscientific.com/en-US/about-us/history. Retrieved 20 Feb 2015. 
    7. ^ "News Releases - Boston Scientific". 
    8. ^ "News Releases - Boston Scientific". 
    9. ^ "News Releases - Boston Scientific". 
    10. ^ "News Releases - Boston Scientific". 
    11. ^ "News Releases - Boston Scientific". 
    12. ^ "News Releases - Boston Scientific". 
    13. ^ "News Releases - Boston Scientific". 
    14. ^ "Guidant battle ends in favor of Boston Scientific". Associated Press. January 25, 2006. Retrieved 2008-02-11. 
    15. ^ "Boston Scientific Completes Combination with Guidant". April 21, 2006. Archived from the original on April 16, 2008. Retrieved 2008-02-11.  Boston Scientific's press release on the acquisition.
    16. ^ "News Releases - Boston Scientific". 
    17. ^ "News Releases - Boston Scientific". 
    18. ^ "News Releases - Boston Scientific". 
    19. ^ "Boston Scientific Spin-off Aiming to Tap Veins Without Causing Infections". August 5, 2008. Retrieved 2009-02-23. 
    20. ^ "News Releases - Boston Scientific". 
    21. ^ Bernton, Hal, "Army Whistle-Blower Fights To Clear Name", Seattle Times, 14 August 2011, p. 1.
    22. ^ "News Releases - Boston Scientific". 
    23. ^ "News Releases - Boston Scientific". 
    24. ^ "News Releases - Boston Scientific". 
    25. ^ "News Releases - Boston Scientific". 
    26. ^ "News Releases - Boston Scientific". 
    27. ^ "News Releases - Boston Scientific". 
    28. ^ "News Releases - Boston Scientific". 
    29. ^ "News Releases - Boston Scientific". 
    30. ^ "News Releases - Boston Scientific". 
    31. ^ "News Releases - Boston Scientific". 
    32. ^ "News Releases - Boston Scientific". 
    33. ^ "News Releases - Boston Scientific". 
    34. ^ McLaughlin, Kim (March 2, 2015). "Boston Scientific Buys Endo Men's Health Unit for .6 Billion". Bloomberg. 
    35. ^ "News Releases - Boston Scientific". 
    36. ^ "News Releases - Boston Scientific". 
    37. ^ "News Releases - Boston Scientific". 
    38. ^ "News Releases - Boston Scientific". 
    39. ^ "News Releases - Boston Scientific". 
    40. ^ "News Releases - Boston Scientific". 
    41. ^ "News Releases - Boston Scientific". 
    42. ^ "News Releases - Boston Scientific". 
    43. ^ "News Releases - Boston Scientific". 
    44. ^ "News Releases - Boston Scientific". 
    45. ^ "News Releases - Boston Scientific". 
    46. ^ Boston Scientific to Pay J&J $1.73B to Settle Stent Patent Disputes, The Wall Street Journal, February 2, 2010
    47. ^ J&J seeks over $5 billion in damages from Boston Scientific at trial. Reuters, 19 November 2014
    48. ^ Jessica Dye (May 28, 2015). "Boston Scientific ordered to pay $100 million in transvaginal mesh trial". Reuters. Retrieved May 14, 2018. 
    49. ^ Scott Pelley (May 13, 2018). "Gynecological mesh: The medical device that has 100,000 women suing, A common surgical implant has generated the largest multi-district litigation since asbestos. 60 Minutes reports on one of the device's manufacturers, Boston Scientific, now facing 48,000 lawsuits". CBS News. Retrieved May 14, 2018. 
    50. ^ Dave Pierce, Executive Vice President, MedSurg, Boston Scientific, President, Urology and Pelvic Health. "Our perspective on the "60 Minutes" report on transvaginal mesh". Boston Scientific. Retrieved May 14, 2018. CS1 maint: Multiple names: authors list (link)
    51. ^ "Urogynecologic Surgical Mesh Implants". Food and Drug Administration. September 19, 2017. Retrieved May 14, 2018. 
    52. ^ Mayo Clinic Staff (July 22, 2017). "Get the facts about transvaginal mesh complications, Concerned about transvaginal mesh complications associated with treatments for pelvic floor disorders? Here's what you need to know". The Mayo Clinic. Retrieved May 14, 2018. 
    53. ^ "Boston Scientific Addresses Japan Business Irregularities". 
    source: https://en.wikipedia.org/wiki/Boston_Scientific[/td_text_with_title]